The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.

Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.

Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.